Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, announced a strategic partnership with Turbine, a ...
Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory mul...
This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipeline Under the terms of the agreement, Nxe...
The demand for nucleic acid therapeutics (NATs) is rapidly altering the therapeutic landscape across a wide range of diseases. Recent industry data highlig...
BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pne...
Phase two collaboration aims to expand access to streamlined genomic workflows for infectious disease research Cepheid, a Danaher company and a leader i...
Strategic partnership enables upskilling of Novo Nordisk’s workforce and places the company at the forefront of AI transformation in healthcare ...
In this exclusive BioPharma Boardroom interaction, Thierry Van Nieuwenhove, CEO of Quotient Sciences, explores why nearly 90% of drug candidates fail and w...
DualityBio announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate ("ADC") trastuzumab pamirtecan ("T-Pam"...
The multi-year collaboration aims to scale molecular data storage infrastructure and unlock breakthrough cost efficiencies by 2030. GenScript Biotech Co...
One Ofichem. One voice. A more connected approach to pharmaceutical partnerships. Ofichem has brought its brands - Ofichem BV, Ofipharma, Ofimedicine, L...
EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio Silo Pharma, Inc. (Nasdaq: SILO...
- Cipla USA Inc. the wholly owned subsidiary of Cipla Limited announced final approval from the U.S. Food and Drug Administration (USFDA) for its Abbrevi...
Government investment will accelerate clinical development and strengthen Aspect’s advanced biomanufacturing capabilities for its bioengineered c...
© 2026 Biopharma Boardroom. All Rights Reserved.
